Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing

NCT00066651 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00066651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00066651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study Of SS1(dsFv)-PE38 Anti-Mesothelin Immunotoxin In Advanced Malignancies: I.V. Infusion QOD Dosing
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2003
Completion date
Not reported
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, fallopian tube cancer, head and neck cancer, lung cancer, malignant mesothelioma, ovarian cancer, pancreatic cancer, primary peritoneal cavity cancer